TABLE 2.
Summary of visits, clinical status, and per protocol treatment in the VIPER-BP intervention arm (n = 1038)
| Baseline | Week 6 day 42 | Week 10 day 70 | Week 14 day 98 | Week 18 day 126 | Week 26 day 182 | |
| Participants | 1085 (100%) | 945 (91.0%) | 872 (84.0%) | 831 (80.1%) | 829 (79.9%) | 857 (82.6%) |
| Mean days of visit | – | 42.5 ± 8.9 | 72.8 ± 12.0 | 102.5 ± 13.8 | 132.1 ± 15.4 | 186.1 ± 19.9 |
| Visit within 7 days of schedule | – | 812/945 (86%) | 678/872 (78%) | 595/831 (72%) | 586/829 (71%) | 502/857 (59%) |
| BP above individual target | 1085 (100%) | 722 (76.4%) | 625 (71.7%) | 536 (64.5%) | 499 (60.2%) | 514 (60.0%) |
| SBP within 1–5 mmHg of target | – | 97 (10.3%) | 110 (12.6%) | 104 (12.5%) | 112 (13.5%) | – |
| Treatment-related adverse event recorded | – | 135 (14.3%) | 148 (17.0%) | 154 (18.5%) | 154 (18.2%) | 141 (16.5%) |
| Per protocol treatment applied | 962/1085 (92.7%) | 701 (74.2%) | 568 (65.1%) | 509 (61.3%) | 541 (65.3%) | – |
VIPER-BP, the Valsartan Intensified Primary carE Reduction of Blood Pressure.